What is MimiVax?
MimiVax operates at the intersection of immunology and oncology, focusing on the development of novel immunotherapies designed to disrupt cancer progression. The company's flagship asset, SurVaxM, is currently undergoing rigorous clinical evaluation, specifically targeting glioblastoma and other complex oncological conditions. By utilizing a sophisticated mechanism to stimulate the immune system against tumor-specific antigens, MimiVax aims to significantly improve survival outcomes and patient quality of life.
Beyond its clinical pipeline, the company serves as a cornerstone of the Buffalo, New York, biomedical ecosystem. Through strategic partnerships and a commitment to translational medicine, MimiVax bridges the gap between academic research and commercial-scale therapeutic delivery. Its market position is defined by a high-barrier-to-entry intellectual property portfolio and a clear regulatory roadmap for its lead immunotherapy candidate.
How much funding has MimiVax raised?
MimiVax has raised a total of $1.6M across 1 funding round:
Private Equity
$1.6M
Private Equity (2015): $1.6M with participation from Buffalo Capital Partners
Key Investors in MimiVax
Buffalo Capital Partners
Buffalo Capital Partners is a private equity firm managed by professionals with extensive experience in leveraged lending, banking, and investment management, providing strategic capital to high-growth enterprises.
What's next for MimiVax?
With the recent influx of capital, MimiVax is expected to prioritize the expansion of its clinical trial footprint and the optimization of its manufacturing processes for SurVaxM. The strategic roadmap likely includes scaling internal research capabilities and pursuing additional collaborative ventures to bolster its pipeline. As the company moves toward potential commercialization, the focus will remain on achieving key regulatory milestones and demonstrating long-term efficacy in patient cohorts. This growth trajectory suggests a shift toward late-stage clinical development, where the company will likely seek to solidify its competitive advantage in the immunotherapy sector through continued data-driven innovation and strategic resource allocation.
See full MimiVax company page
